Ocular Therapeutix, Inc. (NASDAQ:OCUL) is reporting second quarter financial results on Friday 7th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, OCUL is expected to report 2Q20 loss of $ 0.31 per share from revenue of $ 1.50 million.
For the full year, analysts anticipate top line of $ 15.94 million, while looking forward to loss of $ 1.14 per share bottom line.
Previous Quarter Performance
Ocular Therapeutix, Inc. recorded loss for the first quarter of $ 0.41 per share, from the revenue of $ 2.61 million. The quarterly earnings while revenues compared with the same quarter last year.
Street analysts expected Ocular Therapeutix, Inc. to report loss of $ 0.37 per share on revenue of $ 2.84 million for the first quarter. The bottom line results missed street analysts by $ 0.04 or 10.81 percent, at the same time, top line results fell short of analysts by $ 0.23 million or 8.1 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Ocular Therapeutix, Inc.
Stock Performance
The company has a market capital of $ 529.81 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”OCUL” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Ocular Therapeutix, Inc. will be hosting a conference call at 8:30 AM eastern time on 7th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.ocutx.com
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases.
